Moderna Rockets 93% and Merck Jumps 7% as Melanoma Therapy Meets Phase 3 Goal

Moderna and Merck Deliver Historic Breakthrough in Cancer Treatment

Shares of Moderna rocketed 93% to $121.76 in early Wednesday trading after the biotech company and partner Merck announced that their Phase 3 melanoma trial met its primary endpoint. Merck stock climbed 7% to $144.60 on the breakthrough news. The catalyst marks the first positive Phase 3 readout for a personalized mRNA cancer therapy, an outcome that validates a platform Moderna has spent years building. Enrollment for the trial reached 1,137 patients, with two-thirds receiving the combination treatment and the remainder receiving Keytruda alone.

Moderna shares closed Tuesday at $62.96, down 2% on the session, and the stock has already climbed 114% year to date through Tuesday’s close. Merck stock closed Tuesday at $135.17 and is up 30% year to date through Tuesday’s close. If early levels hold, Moderna is on track for its biggest ever single-day gain and could open at more than two-year highs. The historic surge demonstrates investor confidence in the personalized mRNA platform and its potential to revolutionize cancer treatment.

Phase 3 Trial Delivers Statistically Significant Results

The Phase 3 INTerpath-001 trial tested Intismeran Autogene alongside Merck’s immunotherapy Keytruda in patients with high-risk stage IIB-IV melanoma whose tumors had been completely removed by surgery. The combination produced statistically significant and clinically meaningful improvements in recurrence-free survival and in distant metastasis-free survival compared with Keytruda alone. No new safety concerns emerged during the trial, and the study will continue to assess overall survival as a secondary endpoint.

Phase 2b data previously showed a 49% reduction in recurrence or death, and the combination now advances across nine trials targeting six cancer types. The therapy represents a major milestone in oncology, combining personalized mRNA technology with established immunotherapy to create a tailored approach for each patient. Dean Y. Li, President of Merck Research Laboratories, described the findings as reinforcing the promise of a more personalized approach to cancer treatment.

Broader Market Impact Remains Limited

BioNTech, the other major mRNA cancer developer, rose just 1% while the broad XLV ETF gained only 2% as Moderna’s win diluted across holdings. The muted response from the broader healthcare sector suggests investors view this breakthrough as specific to Moderna and Merck rather than a sector-wide catalyst. The divergence highlights how personalized medicine platforms create company-specific value that does not necessarily lift all competitors in the same therapeutic area.

The historic surge in Moderna shares comes after years of investment in mRNA technology beyond COVID-19 vaccines, demonstrating the platform’s versatility and commercial potential. The company now stands to benefit from a validated approach that could extend across multiple cancer types, potentially opening new revenue streams and partnership opportunities. Investors have rewarded Moderna with a valuation that reflects confidence in the long-term prospects of personalized mRNA therapies.

Trial Design and Patient Population

The INTerpath-001 trial enrolled 1,137 patients with high-risk stage IIB-IV melanoma whose tumors had been completely removed by surgery, representing a population at significant risk of recurrence. Two-thirds of participants received Intismeran Autogene plus Keytruda, while the remaining third received Keytruda alone as the control arm. The trial’s primary endpoints focused on recurrence-free survival and distant metastasis-free survival, both critical measures of long-term patient outcomes in adjuvant melanoma treatment.

The safety profile of the combination therapy showed no new concerns beyond those already known for the individual components, which will likely facilitate regulatory review and potential approval. The trial will continue to follow patients for overall survival data, which could further strengthen the clinical and commercial case for the therapy. Moderna and Merck have positioned the therapy as a first-in-class personalized mRNA cancer treatment, potentially setting the standard for future adjuvant therapies in melanoma and beyond.

Expansion Across Multiple Cancer Types

The success in melanoma paves the way for Intismeran Autogene to advance across nine ongoing trials targeting six different cancer types, dramatically expanding the commercial opportunity for both partners. The personalized mRNA platform creates tumor-specific antigens for each patient, theoretically allowing the immune system to recognize and attack cancer cells more effectively. This approach represents a paradigm shift from traditional one-size-fits-all cancer treatments toward truly individualized therapies.

Moderna has invested heavily in the manufacturing and logistics infrastructure required to deliver personalized therapies at scale, a capability that could become a significant competitive advantage. The partnership with Merck provides commercial expertise and an established immunotherapy franchise that complements Moderna’s mRNA platform. Together, the companies now possess a validated foundation for expanding into additional cancer indications and potentially other disease areas where personalized medicine could deliver meaningful clinical benefits.

Analyst Expectations and Market Outlook

Despite the historic stock surge, some analysts caution that Merck did not make the cut in certain top AI stock recommendations, suggesting that even positive clinical data does not guarantee long-term outperformance. The divergence between Moderna’s 93% gain and Merck’s more modest 7% rise reflects the relative impact on each company’s total valuation and product portfolio. For Moderna, the melanoma therapy represents a potential cornerstone asset beyond its COVID-19 franchise, while for Merck, it adds to an already robust oncology pipeline.

The market reaction underscores investor appetite for innovative cancer therapies that combine cutting-edge technology with proven immunotherapy approaches. As the trial continues to generate overall survival data and regulatory submissions advance, both companies could see further upside if the therapy ultimately reaches the market. The success of this Phase 3 trial validates years of research and development in personalized mRNA technology, potentially opening the door for similar approaches across a wide range of cancers and other diseases.